8月8日，博安生物(06955)盘中上涨8.2%，截至15:53，报18.48元/股，成交7.39亿元。 山东博安生物技术股份有限公司是一家生物制药公司，主要业务包括生物药开发、生产和商业化，特别 专注于肿瘤、自身免疫、眼科和代谢疾病领域。目前，公司拥有三款商业化产品，已在中国及包括欧美 在内的海外市场进行生物药产品开发，并有几个在研的创新生物药和生物类似药产品组合，已构建起全 覆盖"研发-生产-商业化"的产业价值链运营体系。 截至2024年年报，博安生物营业总收入7.26亿元、净利润7318.9万元。 8月7日，拟配售4800万新股份，占扩大后股本7.71%，每股配售价16.42港元，较前一收市日折价8.78% (预案)。 本文源自：金融界 作者：行情君 ...

此外，博安生物近日宣布，拟配售总计4800万股股份，预计募集资金净额约7.80亿港元，公司拟将50% 主要用于研发、临床试验及产品制造；20%用于产品商业化以及30%用于补充营运资金和一般企业用 途。值得注意的是，博安生物6月初宣布配售3840万股，净筹约3.96亿元。 消息面上，8月8日，国家药监局官网显示，博安生物申报的度拉糖肽注射液(BA5101)获批上市，用于 成人2型糖尿病患者的血糖控制。这是首款获批上市的国产度拉糖肽生物类似药。据礼来财报，2024年 度拉糖肽全球销售额为52.535亿美元。 博安生物(06955)尾盘飙升逾16%，截至发稿，涨10.89%，报18.94港元，成交额6.45亿港元。 ...

Major Events - Silver诺医药-B (02591) is set to conduct an IPO from August 7 to August 12, with an expected listing date of August 15 [1] - Boan Biotech (06955) plans to place 48 million shares at a discount of approximately 8.78%, aiming to raise about HKD 780 million [1] - Derin Holdings (01709) intends to raise HKD 653.3 million, focusing on the development of blockchain, RWA, and virtual asset businesses [1] - Fuhong Hanlin (02696) received FDA approval to initiate a Phase 1 clinical trial for HLX43, a PD-L1 targeted antibody-drug conjugate for thymic cancer treatment [1] - China Biopharmaceutical (01177) obtained NMPA approval for the Phase II clinical trial application of LM-24C5, a dual antibody targeting CEACAM5/4-1BB [1] Financial Reports - China Mobile (00941) reported a shareholder profit of HKD 84.235 billion, a year-on-year increase of 5.03% [1] - Manulife Financial-S (00945) announced a core profit of CAD 1.7 billion for the second quarter [1] - Swire Properties (01972) reported a basic profit attributable to shareholders of HKD 4.42 billion, a year-on-year growth of 15% [1] - Hutchison Whampoa (00013) posted a net profit of USD 455 million, a significant year-on-year increase of 1663.32% [1] - MGM China (02282) disclosed a net profit of HKD 2.383 billion, a year-on-year decrease of 11.25% [1] - SMIC (00981) reported a shareholder profit of USD 132 million for the second quarter, with a revenue guidance for the third quarter indicating a sequential growth of 5% to 7% [1] - Zai Lab (09688) achieved a total revenue of approximately USD 216 million for the first half of the year, reflecting a year-on-year growth of 15.35% [1] - Innovent Biologics (01801) reported total product revenue exceeding RMB 5.2 billion for the first half of the year, maintaining a strong growth rate of over 35% [1] - Pacific Basin Shipping (02343) announced a profit attributable to shareholders of USD 25.6 million, a year-on-year decrease of 56% [1] - Lee & Man Paper Manufacturing (02314) reported a net profit of HKD 811 million, a year-on-year increase of 0.7%, with an interim dividend of HKD 0.066 per share [1] - Swire Group reported a profit attributable to shareholders of HKD 815 million for the first half of the year, a year-on-year decrease of 79% [1] - Lee & Man Chemical Company (00746) reported a profit increase of 36.0% to HKD 327 million, with an interim dividend of HKD 0.195 per share [1] - Hua Hong Semiconductor (01347) reported a profit attributable to parent company owners of USD 7.952 million for the second quarter, a year-on-year increase of 19.2% [1] - Wharf Real Estate Investment (01997) reported a loss attributable to shareholders of HKD 2.406 billion, a year-on-year increase of 128.71%, with the first interim dividend of HKD 0.066 per share [1] - Dekang Agriculture (02419) issued a profit warning, expecting a year-on-year increase in fair value adjustments of biological assets to approximately RMB 1.1 billion to 1.4 billion [1] - Mongol Mining (00975) issued a profit warning, anticipating a net loss of approximately USD 15 million to 25 million for the first half of the year, marking a shift from profit to loss [1] - Dongfeng Motor Group (00489) issued a profit warning, expecting a decline in net profit attributable to the parent company of 90% to 95% for the first half of the year [1]

Group 1 - Yisou Technology (02550) rose nearly 12.63% after announcing a share subscription agreement with Lightnet Pte. Ltd., acquiring approximately 1.23% equity for $5 million [1] - Maifushi (02556) fell nearly 2.28% despite a profit forecast of RMB 31.8 million to RMB 41 million for the six months ending June 30, 2025, a significant turnaround from a loss of RMB 820 million in the same period last year [1] - New World Development (00086) increased nearly 4.19% after announcing a profit forecast of no less than HKD 800 million for the six months ending June 30, 2025, compared to HKD 75.4 million in the same period last year [2] Group 2 - Cao Cao Travel (02643) surged nearly 15.68% after signing a strategic cooperation memorandum with Victory Securities to explore virtual asset tokenization and stablecoin applications [2] - Boan Bio (06955) dropped nearly 5.06% after announcing a placement of 48 million shares at HKD 16.42 each, aiming to raise approximately HKD 780 million for R&D and operational purposes [2] - Huaxing Capital Holdings (01911) rose nearly 6%, with a year-to-date stock price increase of 1.1 times, as it plans to invest $100 million in Web 3.0 and cryptocurrency assets [3] Group 3 - Cathay Pacific Airways (00293) continued to decline nearly 3% after a report indicated an 8.3% year-on-year increase in net profit for the first half of the year, but operating profit fell short of market expectations [3] - Keep (03650) rose over 10%, with a cumulative increase of over 22% this week, reporting an adjusted net profit of approximately RMB 10 million for the first half of the year [4] - Smoore International (06969) increased nearly 5%, with BAT's new tobacco product revenue growing 2.4% year-on-year, and Smoore is expected to benefit from this growth [4] Group 4 - Xiaomi Group-W (01810) fell over 4% after Nomura raised its target price by 79% to HKD 61 but downgraded its rating to "Neutral" due to limited upside potential [5] - Apple (AAPL.US) rose 5.09% after announcing a commitment to invest an additional $100 billion in U.S. manufacturing, bringing its total investment commitment to $600 billion [6] - McDonald's (MCD.US) increased 2.98% with second-quarter revenue growing 5.4% year-on-year to $6.84 billion, exceeding analyst expectations [6]

格隆汇8月7日｜博安生物(6955.HK)盘中跌超5%，报17.02港元。消息面上，公司公布，拟配售4800万股 新股，相当于扩大后股本约7.71%；每股配售价16.42港元，较昨日收市价18港元折让约8.78%，集资 7.88亿港元。公司拟将所得款项净额7.8亿港元中，约50%用于研发、临床试验、注册文件及制造创新候 选产品；约20%用于已上市及即将上市产品的商业化；及约30%用于补充公司营运资金及一般企业用 途。 来源：格隆汇APP ...

本文源自财华网 预期配售事项所得款项净额(经扣除公司将承担或产生的所有相关费用、成本及开支后)约为7.8亿港元。 公司拟所得款项净额约50%将用于研发、临床试验、注册文件及制造创新候选产品；约20%将用于已上 市及即将上市产品的商业化；及约30%将用于补充公司营运资金及一般企业用途。 【财华社讯】博安生物(06955.HK)公布，于2025年8月6日，公司拟配售4800万股，相当于经配发及发行 配售股份扩大的已发行股份总数约7.71%。配售价为每股16.42港元，较股份于最后交易日在联交所所报 收市价每股18港元折让约8.78%。截至发稿，博安生物跌4.06%，报17.27港元。 ...

Core Viewpoint - The company, Boan Biotechnology, announced a placement agreement to sell 48 million shares, representing approximately 8.36% of its issued shares as of the announcement date [1] Group 1: Placement Details - The placement price is set at HKD 16.42 per share, which reflects an approximate discount of 8.78% compared to the closing price on the last trading day [1] - The expected net proceeds from the placement are approximately HKD 780 million [1] Group 2: Use of Proceeds - About 50% of the proceeds will be allocated for research and development, clinical trials, registration documents, and manufacturing of innovative candidate products [1] - Approximately 20% will be used for the commercialization of already listed and upcoming products [1] - Around 30% will be utilized to supplement the company's working capital and for general corporate purposes [1]

配售价为每股16.42港元较股份于最后交易日在联交所所报收市价每股18.000港元折让约8.78%。 假设总计4800万股配售股份将获出售，配售事项所得款项总额预期将为7.88亿港元。预期配售事项所得 款项净额(经扣除公司将承担或产生的所有相关费用、成本及开支后)约为7.8亿港元。因此，经扣除该等 费用、成本及开支后，配售价净额估计约为每股配售股份16.26港元。 博安生物(06955)发布公告，于2025年8月6日，公司及配售代理订立配售协议，据此，公司同意委任配 售代理，而配售代理同意作为公司的代理促使买方按配售价竭诚购买配售股份，惟须遵守配售协议所载 条款及受当中所载条件规限。 可能根据配售事项出售的配售股份总数为4800万股，相当于：(a)于本公告日期的已发行股份总数约 8.36%;及(b)经配发及发行配售股份扩大的已发行股份总数约7.71%(假设自本公告日期至配售事项完成期 间，除配发及发行配售股份外，已发行股份总数并无变动)。 ...

此次配售预计募集资金总额约7.88亿港元，净额约7.80亿港元。募集资金将主要用于研发、临床试验及 产品制造(约50%)，产品商业化(约20%)，以及补充营运资金和一般企业用途(约30%)。 博安生物宣布，已与配售代理瑞银集团订立配售协议。公司将配售总计4800万股股份，占公告日期已发 行股份总数约8.36%，配售价为每股16.42港元，较最后交易日收市价折让约8.78%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不 負 責，對 其 準 確 性 或 完 整 性 亦 不 發 表 任 何 聲 明，並 明 確 表 示，概 不 就 因 本 公 告 的全部或任何部份內容而產生或因倚賴該等內容而引致的任何損失承擔任何 責 任。 本公告或其任何副本概不得直接或間接在美國或在刊發或派發本公告屬違法 的 任 何 其 他 司 法 權 區 內 刊 發 或 派 發。 本 公 告 僅 供 參 考，並 不 構 成 收 購、購 買 或 認 購 任 何 證 券 的 邀 請 或 要 約。 本 公 告 並 非 亦 不 構 成 在 美 國 出 售 證 券 之 要 約 或 邀 請 之 任 何 部 份。證 券 並 無 亦 不會根據1933年美國證券法（經 修 訂）登 記，且 未 經 登 記 或 獲 豁 免 登 記 規 定，不 得 在 美 國 境 內 提 呈 發 售、出 售 或 以 其 他 方 式 轉 讓。在 美 國 公 開 發 售 任 何 證 券， 均 須 以 刊 發 可 從 本 公 司 取 得 之 招 股 章 程 之 方 式 進 行，而 招 股 章 程 將 載 有 有 關 本 公 司 及 管 理 ...